Kelsie Mozzoni

637 total citations
5 papers, 110 citations indexed

About

Kelsie Mozzoni is a scholar working on Pharmacology, Computational Theory and Mathematics and Molecular Biology. According to data from OpenAlex, Kelsie Mozzoni has authored 5 papers receiving a total of 110 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pharmacology, 4 papers in Computational Theory and Mathematics and 3 papers in Molecular Biology. Recurrent topics in Kelsie Mozzoni's work include Cholinesterase and Neurodegenerative Diseases (5 papers), Computational Drug Discovery Methods (4 papers) and Pharmacological Receptor Mechanisms and Effects (2 papers). Kelsie Mozzoni is often cited by papers focused on Cholinesterase and Neurodegenerative Diseases (5 papers), Computational Drug Discovery Methods (4 papers) and Pharmacological Receptor Mechanisms and Effects (2 papers). Kelsie Mozzoni collaborates with scholars based in United States. Kelsie Mozzoni's co-authors include Hank Safferstein, Susan M. Catalano, Nicholas J. Izzo, Steven T. DeKosky, Lon S. Schneider, Michael Grundman, Roger Morgan, Robert Guttendorf, Jason D. Lickliter and Raymond Yurko and has published in prestigious journals such as Journal of Neurochemistry, Alzheimer s & Dementia and Alzheimer s & Dementia Translational Research & Clinical Interventions.

In The Last Decade

Kelsie Mozzoni

5 papers receiving 106 citations

Peers

Countries citing papers authored by Kelsie Mozzoni

Since Specialization

Citations

This map shows the geographic impact of Kelsie Mozzoni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kelsie Mozzoni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kelsie Mozzoni more than expected).

Fields of papers citing papers by Kelsie Mozzoni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kelsie Mozzoni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kelsie Mozzoni. The network helps show where Kelsie Mozzoni may publish in the future.

Co-authorship network of co-authors of Kelsie Mozzoni

This figure shows the co-authorship network connecting the top 25 collaborators of Kelsie Mozzoni. A scholar is included among the top collaborators of Kelsie Mozzoni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kelsie Mozzoni. Kelsie Mozzoni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

#	Work	Indexed citations
1	Alzheimer’s protection effect of A673T mutation may be driven by lower Aβ oligomer binding affinity 2020 ·Journal of Neurochemistry ·(unknown), Harry LeVine, Nicholas J. Izzo, Raymond Yurko, Kelsie Mozzoni, Courtney Rehak, (unknown), Hank Safferstein, Susan M. Catalano	18
2	P4‐708: CLINICAL BIOMARKER EVIDENCE FOR TARGET ENGAGEMENT, REDUCTION OF SYNAPTIC DAMAGE AND DISEASE MODIFICATION IN ALZHEIMER'S PATIENTS TREATED WITH CT1812 2019 ·Alzheimer s & Dementia ·Lon S. Schneider, Anthony O. Caggiano, Michael Grundman, Steven T. DeKosky, (unknown), Kelsie Mozzoni, Nicholas J. Izzo, Hank Safferstein, Susan M. Catalano	2
3	A phase 1 clinical trial of the sigma‐2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease 2018 ·Alzheimer s & Dementia Translational Research & Clinical Interventions ·Michael Grundman, Roger Morgan, Jason D. Lickliter, Lon S. Schneider, Steven T. DeKosky, Nicholas J. Izzo, Robert Guttendorf, (unknown), (unknown), Kelsie Mozzoni, Hank Safferstein, Susan M. Catalano	80
4	[P4–567]: A PHASE 1 SAFETY TRIAL OF THE Aβ OLIGOMER RECEPTOR ANTAGONIST CT1812 2017 ·Alzheimer s & Dementia ·Susan M. Catalano, Michael Grundman, Lon S. Schneider, Steven T. DeKosky, Roger Morgan, Robert Guttendorf, (unknown), (unknown), Kelsie Mozzoni, Nicholas J. Izzo, Hank Safferstein	4
5	P4‐381: A Two‐Part, Double‐Blind, Placebo‐Controlled, Phase 1 Study of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of CT1812 in Healthy Volunteers 2016 ·Alzheimer s & Dementia ·Susan M. Catalano, Michael Grundman, Lon S. Schneider, Steven T. DeKosky, Roger Morgan, (unknown), (unknown), Kelsie Mozzoni, Nicholas J. Izzo, Hank Safferstein, Jason D. Lickliter	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact